Novogene Precision Medicine 2.0 (NovoPM 2.0) is a comprehensive genomic profiling test for solid tumours that uses Next Generation Sequencing (NGS) technology to analyse 484 cancer-related genes for clinically significant alterations at the DNA level. The genes analysed are known to be relevant to the diagnosis and treatment of various solid tumours according to the National Comprehensive Cancer Network (NCCN) guidelines and medical literature. The test is performed in Novogene’s CAP-accredited laboratory and analysed by in-house bioinformatics specialists. The resulting report provides personalised treatment recommendations for patients based on their genomic profile.
Systems that meet the requirements of national and international standards, including CAP, CLIA and ISO accreditation.
No limit on samples number
Industry-leading turnaround time
Guaranteed Q30 ≥ 85%
Publication-ready results and bioinformatic consultants available for data interpretation
NovoPM 2.0 interrogates the complete coding regions of 468 genes and the introns of 43 genes for all four types of genomic abnormalities: SNV, InDel, CNV and fusion. A comparison of the gene lists between NovoPM 2.0 and the FDA-approved FoundationOne CDx is shown in Figure 1. The mutation status of some of these genes can guide the potential application of multiple FDA-approved targeted and/or immunotherapies as shown in Table below. The other genes are also analyzed for their relevance to the diagnosis and/or treatment of various solid tumors according to the medical literature. The clinical interpretation of detected mutations in those genes is done according to Novogene’s comprehensive in-house oncology knowledgebase constructed based on public resources including GeneCards, CKB, OncoKB, ClinVar PMC, Drugs@FDA, Drug Information Portal (NIH), Selleck, PharmGKB, DGIdb, DRUGBANK, Drugs.com, ClinicalTrials.gov, ICTRP, ChiCTR, KEGG and Cell Signaling. In addition, our oncology knowledgebase incorporates ~1,000 germline BRCA1/2 variants previously reported to be unique in Chinese breast cancer and ovarian cancer patients1.
Figure 1. NovoPM 2.0 vs. FoundationOne CDx
Table 1. Gene targets in NovoPM 2.0 that are associated with FDA-approved or NCCN-recommended therapies
Paediatric sample – EDTA (purple-top) tube
*FFPE: Formalin-fixed, paraffin embedded.
The field is required.